CD47 and neoplasm: A second T cell-dependent mechanism in vivo was documented by Tseng et al., who showed that treatment with an anti-CD47 antibody had a greater effect in wild-type mice with established tumors than in T cell-deficient nude mice with equivalent tumor burden [96].